Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

The objective of this study is to conduct a population pharmacokinetic analysis of caspofungin in a population of patients with moderate and severe acute alcoholic hepatitis or liver disease with Child-Pugh score B and C in order to better characterize pharmacokinetic parameters in case of moderate and severe liver dysfunction.

patients admitted for alcoholic hepatitis or decompensated cirrhosis and Child-Pugh score 7-9 and 10-15 will be included; all patients without invasive aspergillosis.

Inclusion Criteria:

• Liver failure Child-Pugh B and C

Exclusion Criteria:

• Cachexia (BMI < 15 kg/m²)
• Pregnancy
• HIV
• Hepatitis C patients